Antican^®

• Vetco has successfully invented JPJY-B10- a combination drug- as an anticancer agent, which has great potential to treat a variety types of adenocarcinoma in human for example, liver cancer, nasopharyngeal cancer, melanoma and oral cancer etc. Although the clinical targets are various human cancers, JPJY-B10 has been fully developed in Taiwan for treatment of canine perianal gland tumor- under the name Antican^®, which has been launched in Taiwan in Oct. 2017.

  Proven to be Effective and Safe

  In preclinical stage, Antican^® has been consistently proven to be safe and effective across multiple animal species and various cancer types. Besides, FDA also commented that they believe this product is innovative in its mechanism of action, route of administration and probable improved safety profile compared to traditional oncology products, and would fill a clinical need.

  Product Features

  Antican^®, with no chemotherapy side effects, reacts directly on cancer cells. During treatment, proper animal restraint and handling is sufficient. This product is ideal for the following conditions:

  Animal not suitable for anesthesia
  Tumor location that is not easily accessible for surgery
  Tumor size too large which is not suitable for surgery
  Attentive to post-surgery life quality, do not wish to perform amputation
  Allergic to traditional chemotherapy drug
• 

Differs from traditional chemotherapy drug, Antican^® is safe and only has mild side effects, which are mainly minor and self-limiting, such as local pain, mild skin irritation, one-time diarrhea and self-limiting fever. While there is no biological risk of traditional chemotherapy drug, hence, one should not be concerned about the drug causing harm to medical personnel and the owner during treatment.

High Product Quality

To ensure that companion animals receive similar medical treatment standards as humans, the production standard of Antican^® adapted are in line with the human pharmaceutical production requirements, GMP (Good Manufacturing Practices). From utilizing human-use raw materials, to manufacturing, filling, packaging and labeling in production site; strict quality control is adapted to ensure drug stability, safety and efficacy. These compliance safeguard that quality and safe cancer treatment can be delivered to our companion animals. 

Course of treatment

 Two-week duration with total 10 injections given

This product is for veterinarian use only

Moving forward

With comprehensive preclinical data, this anticancer drug is also readily to be developed for human use. Vetco intends to develop and launch JPJY-B10 for human cancer indications through a newly-formed entity.